ArticleArthritis care & research2017
Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study.
Article in Arthritis care & research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Autonomic dysfunction and cardiovascular risk in psoriatic arthritis.Clinical rheumatology · 2023Pooled it
- Comorbidities in psoriatic arthritis: a systematic review and meta-analysis.Rheumatology international · 2021 · on this mapPooled it
- Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.RMD open · 2021Trial
- Cardiovascular Risk in Psoriatic Arthritis in the Treat-to-Target Era: A Focused Expert Narrative Review of Epidemiology, Risk Assessment, Vascular Imaging, and Prevention.Journal of clinical medicine · 2026Review
- Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Neutrophil-to-Lymphocyte Ratio as a Predictor of Cardiovascular Events in Psoriatic Disease: A Retrospective Cohort Study.ACR open rheumatology · 2026Article
- Unveiling the association between low-density lipoprotein cholesterol lowering and fracture risk : real-world evidence from a target trial emulation study.Bone & joint research · 2026Article
- Association of PFAS and Metals with Cardiovascular Disease Risk: Exploring the Mediating Effect of Diet.Environments (Basel, Switzerland) · 2025Article
- Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation.Metabolites · 2025Review
- Association between Life's Crucial 9 and psoriatic arthritis in U.S. adults: a cross-sectional study.Frontiers in medicine · 2025Article
- Prevalence of hyperlipidemia in psoriatic arthritis patients in Riyadh, Saudi Arabia.Saudi medical journal · 2024Article
- Cardio-Rheumatology Insights Into Hypertension: Intersection of Inflammation, Arteries, and Heart.American journal of hypertension · 2024Review
- Rapid ethnographic appraisal of community concepts of and responses to joint pain in Kilimanjaro, Tanzania.BMJ global health · 2024Article
- Investigating causal associations among gut microbiota, metabolites, and psoriatic arthritis: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.Frontiers in immunology · 2024Article
- Cardiovascular comorbidities in psoriatic arthritis: state of the art.Therapeutic advances in musculoskeletal disease · 2024Review
- Clinical and molecular insights into cardiovascular disease in psoriatic patients and the potential protective role of apremilast.Frontiers in immunology · 2024Review
- Rheumatoid arthritis, cardiometabolic comorbidities, and related conditions: need to take action.Frontiers in medicine · 2024Review
- Risk factors for prevalent and incident hypertension in rheumatoid arthritis: data from the Canadian Early Arthritis Cohort.Rheumatology advances in practice · 2024Article
- The Influence of Rheumatoid Arthritis and Osteoarthritis on the Occurrence of Arterial Hypertension: An 8-Year Prospective Clinical Observational Cohort Study.Journal of clinical medicine · 2023Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo examine the prevalence and incidence of cardiovascular (CV) risk factors, including hypertension, hyperlipidemia, diabetes mellitus (DM), and obesity among patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA) compared to the general population, and to examine the treatment of incident CV risk factors in PsA and RA compared to controls.
methodsA cohort study was conducted within The Health Improvement Network, a medical record database in the UK, using data from 1994 to 2014. Patients ages 18-89 years with PsA or RA were matched to controls on practice and start date. The prevalence and incidence of CV risk factors identified by diagnostic codes were calculated. Cox proportional hazards models were used to examine the relative incidence of these CV risk factors. Finally, pharmacologic therapies for incident CV risk factors were examined.
resultsStudy subjects included patients with PsA (n = 12,548), RA (n = 53,215), and controls (n = 389,269). The prevalence of all CV risk factors was significantly elevated in PsA. Only the prevalence of DM and obesity was increased in RA. Incidence of hypertension, hyperlipidemia, and DM was elevated in PsA and RA. Receipt of therapy within 1 year following incident diagnosis of CV risk factors was not substantially different between the groups; approximately 85%, 65%, and 45% of patients received prescriptions for hypertension, hyperlipidemia, and DM, respectively.
conclusionPatients with PsA have an increased prevalence of CV risk factors, and both patients with PsA and patients with RA have increased incidence of a new diagnosis of CV risk factors. Pharmacologic treatment of CV risk factors in patients with PsA and RA was similar to controls in the UK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.